These results, in the line of our previous study, indicated that AXL-low-expressing EGFR-mutated NSCLC cells were more sensitive to osimertinib than AXL-high-expressing EGFR-mutated NSCLC cells. Here, EGFR is linked to non-small cell lung carcinoma.